New shot for eczema shows promise in Mid-Stage trial
NCT ID NCT07330934
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called IBI356 in about 400 adults with moderate to severe atopic dermatitis (eczema). Participants receive either IBI356, dupilumab (an existing treatment), or a placebo by injection. The main goal is to see if IBI356 reduces eczema severity and itching compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI356 (a drug given by injection)
- What this could lead to
- If successful, this could point toward a new treatment option for people with moderate to severe eczema that doesn't respond well to topical creams.
- What could go wrong
- This is an early Phase 2 trial, so it's not yet proven to work. The drug may not be more effective than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?